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Background: Gene expression profiling of the postmortem human brain is part of the effort to understand the
neuropathological underpinnings of schizophrenia. Existing microarray studies have identified a large number of
genes as candidates, but efforts to generate an integrated view of molecular and cellular changes underlying the
illness are few. Here, we have applied a novel approach to combining coexpression data across seven postmortem
human brain studies of schizophrenia.
Results: We generated separate coexpression networks for the control and schizophrenia prefrontal cortex and
found that differences in global network properties were small. We analyzed gene coexpression relationships of
previously identified differentially expressed ‘schizophrenia genes’. Evaluation of network properties revealed
differences for the up- and down-regulated ‘schizophrenia genes’ , with clustering coefficient displaying particularly
interesting trends. We identified modules of coexpressed genes in each network and characterized them according
to disease association and cell type specificity. Functional enrichment analysis of modules in each network revealed
that genes with altered expression in schizophrenia associate with modules representing biological processes such
as oxidative phosphorylation, myelination, synaptic transmission and immune function. Although a immune-function
enriched module was found in both networks, many of the genes in the modules were different. Specifically, a
decrease in clustering of immune activation genes in the schizophrenia network was coupled with the loss of various
astrocyte marker genes and the schizophrenia candidate genes.
Conclusion: Our novel network-based approach for evaluating gene coexpression provides results that converge with
existing evidence from genetic and genomic studies to support an immunological link to the pathophysiology of
schizophrenia.
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Schizophrenia is a severe psychiatric disorder with an
elusive etiology. Gene expression profiling of the post-
mortem human brain has been frequently used as a
means to investigate patterns of molecular disruption in
the brains of patients with schizophrenia. One of the
most common types of analysis applied to expression
profiling data is differential expression; which is used to* Correspondence: paul@chibi.ubc.ca
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reproduction in any medium, provided the oridentify over- or under-expressed genes associated with the
illness. Candidate genes identified from expression profiling
studies in schizophrenia have implicated alterations in
different cellular systems, including myelination, synaptic
transmission, metabolism, and ubiquitination [1]. These
findings are not always replicated across studies, nor have
they been successfully integrated into a comprehensive
biological framework.
In our previous work, we used a large combined
cohort to identify a meta-signature of genes which are
consistently differentially expressed in the prefrontal cor-
tex of patients with schizophrenia [2]. The functions
reflected in these genes are diverse and the interactions
among them are largely unexplored. Because genetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Summary of demographic variables across
combined cohort
Control Schizophrenia P-value
Number of Subjects 153 153
Age 56.25 ± 20 55.27 ± 19 p = 0.67
Sex 101 M : 52 F 113 M : 40 F p = 0.1
Brain pH 6.5 ± 0.28 6.39 ± 0.29 p = 0.001
PMI 21.95 ± 15.3 22.65 ± 15.2 p = 0.69
F, female; M, male; PMI, post-mortem interval. There were 319 samples
collected across seven datasets of which 306 passed quality control analysis.
The summary demographics (mean ± standard deviation) and t- test p-values
for group differences are shown for those subjects used in the analysis. For
sex we report the p-value generated from a chi-squared test for equality
of proportions.
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genes (at the biochemical, physical interaction, genetic
or regulatory levels), it is attractive to apply gene
coexpression network analysis to aid in interpretation.
In general, gene networks can be analyzed to identify
higher-level features of gene-gene relationships based on
graph theoretic considerations such as node degree or
clustering coefficient [3-5]. Evaluating the broader net-
work structure allows us to detect modularity in the
graph, or groups of densely connected nodes with sparse
connections between groups. Characterization of these
‘modules’ can convey useful information as they may be
associated with specific molecular complexes or func-
tions, yielding hypotheses that would be difficult to as-
certain based on a gene-by-gene analysis. It is important
to note that the terminology “gene coexpression net-
work” refers to a sparse representation of the correlation
structure among genes, and that such networks are not
amenable to straightforward interpretation in the way
that protein interaction or metabolic networks are.
However, a key advantage of coexpression is that there is
relatively abundant data, so “condition-specific networks”
can be constructed. Thus one can evaluate differences be-
tween condition-specific networks to help elucidate systems
level molecular dysfunction.
Such coexpression network analyses have recently
been applied to a number of postmortem human brain
expression profiling datasets for examining general tran-
scriptome patterns of the CNS [6], and to interrogate
the molecular basis of neuropsychiatric disease [7-10].
Torkamani and colleagues [8] conducted a network ana-
lysis by combining two independent schizophrenia ex-
pression profiling datasets. Expression data was merged
across control and schizophrenia cohorts and modules
of coexpressed genes were characterized according to
disease characterization, cell type specificity and the ef-
fects of aging. A more recent cross-cortical network
study was carried out by Roussos et al. [10] using control
and schizophrenia samples across four different brain re-
gions. Discrete modules of coexpressed genes displayed
high preservation between control and schizophrenia
networks for all but one module. Brain regional differ-
ences were assessed with an analysis of variance com-
parison of module eigengene expression, with changes
only observed in the control network. Chen et al. [11]
also explored networks using combined data from
schizophrenics and controls. Two modules were associ-
ated with genes differentially expressed with disease
across the datasets; one which was specific to cerebellar
cortex and the other identified across all brain regions.
They did not report any differences in networks between
schizophrenics and controls. Although Chen et al. used
four data sets, they were not independent as three of the
datasets used samples from the same brain collection.In this study, we applied coexpression network analysis
to seven independent gene expression studies of the
prefrontal cortex to demonstrate, in agreement with
previous studies, an overall similarity in transcriptome
organization between healthy controls and individuals
with schizophrenia. We then examined network proper-
ties of genes we previously reported to be differentially
expressed in schizophrenia [2] within each network to
reveal features of these genes that are not observed with
other functional gene groups or other brain-related
disease gene sets. Finally, using a network clustering ap-
proach, we found evidence for functional dysregulation
of immune-related processes in schizophrenia. Our re-
sults complement previous gene expression and genetics
evidence supporting an immunological aspect of the
disorder.
Results
We constructed two gene coexpression networks; one
representing the control human prefrontal cortex and
the other representing the prefrontal cortex in schizo-
phrenia (referred to as CTL and SZ, respectively). The
schizophrenia and control groups had no significant dif-
ferences in age and PMI (Table 1). Sex differences were
assessed by use of a chi-squared test for equality of
proportion, and we observed no significant difference
(p = 0.1). Brain pH was significantly different (t-test;
p = 0.001). Each network was comprised of 12,582 genes
(nodes), and 392,606 coexpression ‘links’ among them.
The two networks had similar values in the average clus-
tering coefficient (p > 0.1), but average shortest path
length across nodes differed slightly (p < 0.01). These
network properties are summarized in Table 2. Both net-
works exhibited a ‘heavy-tailed’ node degree distribution,
with most of the genes interacting with few partners and
a small proportion of genes displaying ‘hub’-like behav-
iour interacting with many genes. In the literature, such
distributions are sometimes described as ‘scale free’. We
used a linear regression of the log-scale node degree dis-
tribution to examine this in our networks (Figure 1).
Table 2 Whole network properties of the control and
schizophrenia brain networks
Control Schizophrenia
Non-connected nodes 2356 2288
Maximum node degree 747 935
Mean node degree 77 76
Shortest path length 3.34 3.32
Cluster coefficient 0.29 0.29
log-log fit (R2) 0.857 0.872
Number of modules 25 25
Figure 2 Comparing node degree between networks. To assess
the node degree differences between networks, values of the node
degree in the control network were plotted against the number of
edges retained in the schizophrenia network. Each gene is
represented by a dot in the plot, and all 12,582 genes were plotted.
The presence of data points that deviate from the identity line
indicate differences in gene-to-gene connections between the two
networks. A histogram is also provided (inset) to illustrate that the
distribution mean of the overlap is about fifty percent.
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node degree distribution, (CTL R2 = 0.857; SZ R2 =
0.872), the fit is not good at the extremes. Based on
more stringent criteria (which we endorse), our net-
works are not ‘scale-free’ [12]. However, the ‘heavy-
tailed’ nature of the node degree distributions in our
networks is typical of other ‘biologically relevant’ net-
works cited in the literature [13,14].
The small differences in global network properties ob-
served between CTL and SZ suggests that there is an
overall common coexpression structure of the prefrontal
cortex. Fifty-seven percent of the edges (224,384 links)
are the same in the two networks, much higher than
expected by chance. The remaining 168,222 edges are
not shared between the two networks (Figure 2). Subtle
differences between the networks are also indicated by a
higher maximum node degree in SZ (935) than CTL
(737), and the increased number of non-connected
nodes in CTL (2356) compared to SZ (2288). These dif-
ferences could indicate subtle biological differences be-
tween the two networks, but are presumably at least
partly due to the effect of noise.
In addition to comparing average network properties
across the SZ and CTL networks to each other, we com-
pared each separately to a node degree-matched randomFigure 1 Connectivity distribution of control and schizophrenia netw
network (B) connectivity distribution on a log10-log10 scale. Plotted on the
the corresponding number of links on the y-axis.network (see Methods). For features based on connectiv-
ity (i.e. shortest path length and clustering coefficient),
we found the observed distributions of both networks to
be higher than compared to random networks. Shortest
path length displayed slightly higher values than found
in randomized networks (Figure 3A, C). Additionally,
genes showed an increased clustering into local commu-
nities compared to genes from a randomized network
with identical degree distribution (Figure 3B, D). Thus
while, the SZ and CTL networks are similar, they are
also clearly distinct from random networks with the
same node degree distribution.orks. The control brain network (A) and the schizophrenia brain
x-axis is the number of links versus the number of genes that have
Figure 3 Comparison to random network distributions. For each network, we generated a corresponding random network by swapping
edges and maintaining the same node degree distribution. (A, C) Shortest path length distribution of real networks are shifted slightly higher
than corresponding random network distributions, but distributions between CTL and SZ are similar. Grey histograms reflect values from the
random network, and black histograms represent the real network data. (B, D) Genes cluster into local communities with high number of
interconnections compared to corresponding random networks. Black dots represent real network data and grey dots represent random
network data.
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gene groups, focusing on our previously identified meta-
signature of genes differentially expressed in schizophre-
nia [2]. The meta-signature of 94 genes (25 up-regulated
and 69 down-regulated) will be referred to as SZUP
and SZDOWN, respectively. Network properties were
assessed for each gene set individually by taking an aver-
age across all genes in the group. These results are
summarized in Table 3. For each gene set we computed
the average values for shortest path length, cluster coef-
ficient and node degree and evaluated differences ob-
served between the control and schizophrenia networks.
In general, both gene sets had a low mean node degree
with respect to the network degree distribution of CTL
and SZ, tending not to be ‘hubs’. For the SZUP gene set,
we found higher node degree, shorter path length and
an increased clustering coefficient in the SZ network,
though these differences were not statistically significant
(Wilcoxon- Rank Sum test p > 0.05). Conversely, the
SZDOWN gene set exhibited a decreased node degree,
larger path length and a lower clustering coefficient(Wilcoxon- Rank Sum test p = 0.05) in the SZ network.
Thus, the properties of each gene set displayed an appar-
ent trend between networks and those trends were ob-
served to be opposite between the two gene sets.
The trends observed for SZUP and SZDOWN be-
tween the two networks were small and only marginally
significant. To evaluate whether each of the individual
gene set values were unusual in the networks we
implemented three different methods of control. A first
control was supplied by comparing observed network
measures for SZUP and SZDOWN to a background
distribution of 1000 randomly selected gene sets
of matched size and node degree (see Methods). The
difference between the observed values and background
was assessed by computing z-scores and p-values, as
reported in Table 3. Our strongest result was for the
clustering coefficient of both gene sets. The p-values for
the SZUP clustering coefficient indicate that the high
value in SZ is significant when compared to a back-
ground distribution (p = 0.005). For SZDOWN, the high
clustering coefficient in CTL showed a trend difference





CTL SZ CTL SZ
Node degree
Mean 63.9 83.5 127.4 106.2
Non-interacting nodes 2 2 7 3
Edges (within gene set) 12 23 129 144
Shortest Path
Mean 3.28 3.14 3.31 3.48
Random gene set comparison
Z-score −0.58 −0.91 3.15 4.46
p-value 0.23 0.15 0 0
Cluster Coefficient
Mean 0.35 0.38 0.32* 0.27*
Random gene set comparison
Z-score 1.11 2.47 1.51 −0.607
p-value 0.14 0.005 0.06 0.28
*Difference is significant between CTL and SZ at p = 0.05.
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gether, these results converge to highlight that the gene
neighbouring meta-signature gene sets are unusually
highly coexpressed, with the SZUP genes displaying this
property in the SZ network and the SZDOWN genes
tending to display this in the CTL network.
A second control was applied to examine whether or
not the properties observed for SZUP and SZDOWN
are a feature of other functionally grouped sets of genes.
This is a more stringent control than simply comparing
to random gene sets, because we are interested in prop-
erties of our genes that are unusual in schizophrenia
compared to other functionally related groups of genes.
We created 3,230 different functional gene sets based on
GO terms and their associated genes. We assessed net-
work measures for each functional gene set and com-
pared the resulting z-scores to values for SZUP and
SZDOWN (Figure 4). For the clustering coefficient, the
z-score for SZUP is more distinguishable from GO
group values in the SZ network compared to CTL. The
opposite is true for the SZDOWN z-score values. Thus,
the clustering coefficient is a unique property of our
meta-signature genes not observed with other functional
gene sets.
We next evaluated whether our meta-signature gene
sets share network properties with gene sets associated
with other brain-related disorders. We assembled gene
sets for five different disorders, mostly based on findings
from genetic association studies. For each disease gene
set, z-scores were computed based on a background dis-
tribution and compared against the GO group z-scores
in each network (Additional file 1: Table S1). Ofparticular interest are the results observed for clustering
coefficient in the two networks. Interestingly, the
Alzheimer’s disease gene group (Figure 4, red arrows)
exhibited strikingly similar properties to SZUP in both
networks despite having only one overlapping gene. Not-
ably, the Parkinson’s disease gene group (Figure 4, blue
arrows) follows a similar but more subtle trend as
SZDOWN.
One concern is that these features are particular prop-
erties of the data sets we analyzed. In the absence of suf-
ficient independent data, we assessed the robustness of
the network measures observed for SZUP and
SZDOWN using a jackknife procedure. In this process,
we removed one of the seven datasets and regenerated
aggregate CTL and SZ networks on the remaining six,
for each study in turn. This yields seven pairs of jack-
knife networks. For each jackknifed network, the average
shortest path length and clustering coefficient was com-
puted for SZUP and SZDOWN and values were com-
pared between networks (Additional file 2: Figure S1).
For SZUP, we observed a general agreement of increas-
ing clustering coefficient and consistently decreasing
path length between CTL and SZ across all iterations.
For SZDOWN, we found that only the clustering coeffi-
cient effects were robust to removing single data sets;
the path length results proved to be more sensitive.
Taken as a whole, these results are consistent with subtle
network property differences for the SZUP and
SZDOWN genes between the two networks.
Our analysis to this point examined either the entire
networks or used supervised approaches to select sets of
genes for analysis. We complemented this with an un-
supervised method based on clustering [5]. This analysis
was motivated in part by the observation that the meta-
signature gene sets showed significant modularity differ-
ences between CTL and SZ. We hypothesized that there
might be additional differences, beyond the parts of the
network involving the meta-signature genes, or that this
analysis might uncover additional features of the meta-
signatures. Clustering resulted in 25 modules of varying
sizes, in each network. An overlap comparison between
the two sets of modules revealed strongly “matching”
modules for 15 modules (p < 0.001, hypergeometric test;
Figure 5), prompting further characterization of these
modules according to disease association, cell-type spe-
cificity and functional roles.
We identified five modules in each network which
displayed the most significant association with genes
differentially expressed in schizophrenia (Wilcoxon
rank-sum test; p < << 0.001), summarized in Table 4
(a list of all network modules is provided in Additional
file 3: Table S2). In order to functionally characterize
coexpression modules we cross-referenced the module
gene lists with published lists of genes encoding markers
Figure 4 Comparison of gene set properties to functional GO groups. Histograms represent z-score distributions for cluster coefficient (A, B)
and shortest path length (C, D) computed across 3,230 different GO groups in the control and schizophrenia networks. Z-scores represent the
difference between the mean value of the network measure of the GO group compared to the mean of random gene sets of the same size and
matched node degree. Dashed lines plotted represent the z-score obtained for the down-regulated meta-signature gene set and solid lines
represent the z-score obtained for the up-regulated gene set. Z-score values for selected brain-related disease gene sets are displayed as
coloured arrows on the x-axis. ALZ Alzheimer’s disease; PD Parkinson’s disease.
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Table S3) and examined functional roles by GO enrich-
ment (Additional file 5: Table S4 and Additional file 6:
Table S5). The top schizophrenia-associated module in
each network showed a significant enrichment of neuronal
markers as well as genes belonging to GO categories
related to the electron transport chain and oxidative
phosphorylation (Module CTL24 and Module SZ3). A large
proportion of the SZDOWN genes were also contained
in this module, in both networks. Both networks alsoidentified a module enriched for genes belonging to
immune-related GO categories (Module CTL1 and
Module SZ15). These modules were highly similar between
networks, with a 71 percent overlap in gene membership
and both associated with schizophrenia disease status. Cell
type enrichment of this module in the control network
identified 44 astrocyte marker genes (at low stringency
threshold). Interestingly, the corresponding module in the
schizophrenia network was reduced to eleven astrocyte
marker genes. Also, we observed three SZUP genes
Figure 5 Heatmap comparison of modules between networks.
Each network was clustered using WGCNA-based methods. Modules
were compared between networks by computing the number of
overlapping genes and a percent overlap was computed by taking
the module of smaller size as the denominator. For each module
pair the percent overlap is plotted with the scale provided.











(25 genes) (73 genes)
Oxidative
phosphorylation
CTL24 1996 0 34***
Glutamine
metabolism
CTL20 504 7*** 0
Myelination CTL25 749 2 0
Immune response CTL1 329 3** 0
Synaptic
transmission










(25 genes) (73 genes)
Oxidative
phosphorylation
SZ3 1144 0 34***
Glutamine
metabolism
SZ9 717 12*** 1
Myelination SZ20 711 2 0
Immune response SZ15 198 0 0
Ubiquitination SZ2 1424 0 12
The top five modules in each network were characterized by enrichment of
genes that are differentially expressed in schizophrenia. Module themes were
assigned based on Gene Ontology enrichment analysis. Disease effect p-values
were computed by entering the t-statistic for the disease effect of each gene
into a Wilcoxon rank-sum test by module. For all modules listed the disease
effect p-values are p < << 0.001 and values can be found in the supplement.
SZUP and SZDOWN are the up- and down-regulated schizophrenia gene sets
previously identified in our meta-analysis [2]. **p < 0.01; ***p < < 0.001.
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control network, but not in the schizophrenia network.
The next two sets of modules that showed significant
association with schizophrenia were also notable in high
enrichment of cell-type marker genes. Module CTL25
and Module SZ20 were both significantly enriched for
oligodendrocyte markers genes (e.g. OLIG2, MBP,
MAG) with a 61 percent overlap in total gene member-
ship, and each contained two SZUP genes. Highly
ranked GO terms from functional enrichment analysis
of each module included the presence of terms such as
“ensheathment of neurons” and “regulation of action po-
tential” suggesting this is was a myelination-related
module. In contrast, modules CTL20 and SZ9 (which
have 71 percent overlap in gene membership) were sig-
nificantly enriched for astrocyte marker genes (Table 5;
p < << 0.001). The common functional role suggested by
GO enrichment centered around glutamine metabolism
(e.g. GAD1, GAD2; see Additional file 5: Table S4 and
Additional file 6: Table S5). SZUP genes also identified
with this module, with a slightly higher number of genes
identified in the SZ network (Table 3; p < < 0.001).
The final top disease-associated modules from each
network, CTL18 and SZ2, were each associated with dif-
ferent cellular processes. Module CTL18 was enriched
for neuronal marker genes and functional enrichment
analysis revealed an association with genes related toneurotransmitter secretion. Furthermore, ten of the
SZDOWN genes overlapped with this module. In the
schizophrenia network, twelve SZDOWN genes (none of
which overlap with the previous ten) were identified
in Module SZ2. Module SZ2 is also neuron marker
enriched but is associated with genes involved in
ubiquitination. The two modules showed very little over-
lap with each other in terms of gene membership (with
only six genes in common) and each highlighted differ-
ent functional roles, yet both modules exhibited an asso-
ciation with schizophrenia in their respective networks.
We next evaluated the impact of covariates on our re-
sults by using expression changes known to be associ-
ated with age, brain pH and sex. Gene lists for these
factors were compiled from a previous study of healthy
control postmortem brain [16], and hypergeometric
probabilities were computed to evaluate the significance
of overlap with each module (Additional file 7: Table S6).
No significant overlap was observed with the sex genes in
either network. The age and pH genes displayed enrich-
ment across the top modules which was mostly consistent
Table 5 Cell-type marker enrichment of coexpression
modules in each network
Control Network






CTL24 43 253*** 48
Glutamine
metabolism
CTL20 23* 9 166***
Myelination CTL25 115*** 16 42
Immune-related CTL1 7 10 44***
Synaptic
transmission
CTL18 7 85*** 9
Schizophrenia Network






SZ3 23 181*** 22
Glutamine
metabolism
SZ9 41*** 20 203***
Myelination SZ20 109*** 16 28
Immune-related SZ15 3 4 11
Ubiquitination SZ2 34 157*** 36
For the top disease-associated clusters in each network we report the number
of genes that overlap with published lists of cell-type marker genes for
oligodendrocytes , neurons, and astrocyte marker genes provided by [15]. Cell-
type enrichment for all modules in each network and results for high
stringency lists (> 10-fold) can be found in Additional file 4: Table 1.
Hypergeometric probabilities were computed to evaluate significance of
overlap. *p < 0.05; ***p < < 0.001.
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ever, differential enrichment was observed for the immune
response module, a trend similar to what we observed
with SZUP genes and astrocyte marker genes. Expression
data for the age and pH genes from the immune response
module were plotted and fold change values were com-
puted to examine the extent to which these genes might
be affecting the network changes we observed (Additional
file 8: Figure S2). We found expression to be variable
within each cohort and differences in mean expression be-
tween cohorts were very small and not significant. Thus,
it seems unlikely that there are large confounding effects
of age and pH driving the changes we see in coexpression
clustering between the two networks. We also addressed
medication effects by cross-referencing lists of gene ex-
pression changes associated with lifetime antipsychotic
use, to the top modules identified in our network analysis.
The SMRI Online Genomics Database (https://www.
stanleygenomics.org/) provides gene lists for several demo-
graphic variables which have been independently assessed
using only the diseased subsets of each dataset. Fromthe database we extracted significant gene lists (p < 0.001;
FC > 1.2) pertaining to the effects of lifetime antipsy-
chotics (69 genes) in subjects with schizophrenia. In the
control network, a total of 34 medication-associated
genes overlapped with our top modules, with the lar-
gest number found in the immune response module
(Additional file 7: Table S6). In the schizophrenia network,
roughly the same number of genes are re-distributed
across the modules, but a significant overlap with the
immune response module remains.
Discussion
Our network-based approach for evaluating gene
coexpression provides a novel assessment of coexpression
patterns across seven large schizophrenia microarray
datasets. We implemented a rank aggregation approach
for network analysis revealing interesting patterns of
molecular connectivity in the control and schizophrenia
postmortem human brain. Overall, the two coexpression
networks were very similar to one another. This is consist-
ent with existing findings from network analysis in
schizophrenia [8,10,11]. The control and schizophrenia
networks shared a similar node degree distribution, and
average values of path length and clustering coefficient
taken across all nodes in the network were not signifi-
cantly different. However, closer inspection revealed dif-
ferences of potential biological significance.
To evaluate differences in gene-gene connectivity be-
tween networks, we initially focused on the network
properties of 95 differentially expressed ‘schizophrenia
genes’ as reported in our previous study of these same
data sets [2]. This gene list was divided into two groups:
1) genes which are up-regulated in schizophrenia and 2)
genes which are down-regulated in schizophrenia. We
examined the network properties of each gene set within
the control and schizophrenia networks and identified
distinguishing features of our ‘schizophrenia genes’. The
clustering coefficient, a measure which gives us insight
into the community structure of nodes, proved to be an
interesting characteristic of both gene sets. Importantly,
we applied control protocols to demonstrate that this
differential coexpression among the neighbourhood of
‘schizophrenia genes’ is not observed with other groups
of “functionally related” genes and most other brain-
related disease gene groups.
We also performed an assessment of modularity across
all nodes in each network. Our results were comparable
to two module coexpression analyses previously
conducted in schizophrenia. The top disease-associated
module in both networks was enriched for genes in-
volved in oxidative phosphorylation and energy produc-
tion This is consistent with results from Torkamani and
colleagues [8] in which a combined network was gener-
ated from two expression datasets, both of which were
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body of evidence suggesting mitochondrial dysfunction
and defects in brain metabolism leading to oxidative
stress in schizophrenia [17,18]. An oligodendrocyte
marker enriched module was also identified in both
CTL and SZ networks of our study and supported with
the association of relevant GO terms related to myelin-
ation. In agreement, Roussos et al. [10] identified their
top schizophrenia-associated module as highly enriched
for oligodendrocyte marker genes as well as for genes asso-
ciated with cytoskeleton rearrangement, axonal guidance
and synaptogenesis. We note that the data used by Roussos
et al. includes some samples contained in the Haroutunian
dataset we used, albeit preprocessed in a different way
(Table 6). The association of a myelination-related module
with schizophrenia is in line with a wide range of reported
white matter abnormalities linked to the illness [23] and
genetic studies that have contributed a number of myelin
and oligodendrocyte –related genes as candidate genes
(e.g. APOD, PLP1, MAG) [24-26]. Torkamani and col-
leagues also identified an oligodendrocyte/myelin-related
module in their network, but they did not observe any asso-
ciation with genes differentially expressed in schizophrenia.
In our analysis, an ‘immune’ module consistently
appeared in both networks. While many genes in this
module were conserved between the two networks, we
found a number of differences suggesting alteration of
immune-related processes in schizophrenia. In the con-
trol network, the immune response module was much
larger in size and contained four times as many astrocyte
marker genes (at low-stringency threshold) than in the
schizophrenia network. A list of microglia marker genes
were obtained from Bedard et al. (2007) [27] and also
cross-referenced with top modules from each network.
The numbers of overlapping genes with each module
were few and did not change between the two networks.
Although microglia are considered the resident macro-
phages of the brain providing the main arm of immune
defense in the CNS, much evidence suggests that astro-
cytes also play an important role in the local regulationTable 6 Datasets used in coexpression network analysis
Dataset Reference Microarray
Platform
Stanley Bahn SMRI database HG-U133A
Stanley AltarC SMRI database HG-U133A
*Mclean HBTRC HG-U133A
Mirnics Garbett K. et al., 2008 [19] HG-U133A/B
*Haroutunian Katsel P. et al., 2005 [20] HG-U133A/B
GSE17612 Maycox P. et al., 2009 [21] HG-U133 Plus
*GSE21138 Narayan S. et al., 2008 [22] HG-U133 Plus
SMRI, Stanley Medical Research Institute; HBTRC, Harvard Brain Tissue Resource Cen
*Samples from these datasets have been used in previous coexpression network stof immune reactivity [28]. In the control network im-
mune module, 31 of the 44 overlapping astrocyte marker
genes were coexpressed with one or more immune acti-
vation genes (Figure 6). Moreover, most of those astro-
cyte marker genes do not appear in the schizophrenia
network module as a result of the loss of the immune
activation genes. Torkamani et al. also identified an im-
mune module, however, similar to the myelination mod-
ule they failed to find any association with differentially
expressed schizophrenia genes. Importantly, in our ana-
lysis three of the SZUP genes, specifically FTL, BAZ1A
and TMEM176A, were identified in this module in CTL
but not in SZ.
BAZ1A encodes a subunit of the chromatin assembly
factor (ACF), which together with other proteins com-
prises the chromatin remodeling complex. Although it is
not directly associated with the immune system, we
found that it was coexpressed with a number of immune
activation genes (Figure 6), suggesting a possible role in
the transcriptional regulation of immune related genes.
TMEM176A was also coexpressed with immune-related
genes, complement component 4A (C4A) and complement
component 4B (C4B), both of which are also not found in
the SZ immune module (Figure 6). TMEM176A encodes a
transmembrane protein, which together with TMEM176B
when overexpressed has been shown to block dendritic cell
maturation in rats [29]. Dendritic cells (DC) are immune
cells found in most major organs, and their ability to regu-
late immunity is dependent on DC maturation. The brain
has long been considered devoid of DC in the absence of
inflammation, with microglia charged with many functional
attributes commonly ascribed to DC. However, recent evi-
dence has illustrated that DC are found in various tissue
reservoirs within the steady-state CNS and are also poten-
tial players in brain immune surveillance [30].
Genes differentially expressed between schizophrenia
subjects and healthy controls have also been identified
through a recent combined analysis conducted on six of
the same datasets used in our study [31]. Perez-Santiago
et al. identified 117 up-regulated and 43 down-regulatedBrain region(s) No. of Subjects
CTL:SZ
Frontal BA46 31: 34
Frontal BA46/10 11: 9
Prefrontal cortex (BA9) 26: 19
Prefrontal cortex (BA46) 6: 9
Frontal (BA10/46) 29: 31
2.0 Anterior prefrontal cortex (BA10) 21: 26
2.0 Frontal (BA46) 29: 25
tre (Mclean66 collection).
udies of schizophrenia [8,10].
Figure 6 Gene membership differences for the ‘immune’ module between networks. A) Visualization of the ‘immune’ module in the
control network is depicted by taking 28 immune activation genes (GO:002253) form the module and their associated connections within the
module. This resulted in a sub-module of 229 nodes and 672 edges. Immune activation genes are represented by the larger nodes on the outer
ring, astrocyte marker genes are represented by the smaller nodes on the inner ring and ‘schizophrenia genes’ are represented by diamond
shaped nodes. Lighter colored nodes indicate the gene is not present in the schizophrenia network immune module while darker colored nodes
indicate the gene is retained. B) and C) Bar graphs were used to illustrate the difference in cell-type marker membership for the ‘immune’
module in the two networks (using the low-stringency list).
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and down- meta-signatures, respectively. The genes
from Perez-Santiago et al. displayed a similar enrichment
pattern as the Mistry et al. signature genes in the top
modules in each of our networks. Specifically, the up-
regulated genes showed a trend that coincides with trends
observed with the astrocyte marker genes and SZUP genes.
In the control network, the immune module contains 44
up-regulated genes and in the schizophrenia network the
number of genes in the immune module is reduced to 19
genes. These findings provide additional support to our dis-
cussion on genes up-regulated in schizophrenia and alter-
ation of immune-related processes.
The immunological link to the pathophysiology of
schizophrenia suggested from our network analysis is
not a new concept. Linkage and GWAS support an asso-
ciation of a broad section of markers in the major histo-
compatibility complex (MHC) region at 6p21.33 withschizophrenia [32,33] and many immune-related genes,
genetic variants and haplotypes are also implicated in
schizophrenia [34-36]. Several studies of gene expression
in the postmortem PFC have reported alterations in
immune and stress-response genes in subjects with
schizophrenia [37-39]. Additionally, the investigation of
gene expression in peripheral blood mononuclear cells
(PBMCs) of drug-naïve schizophrenia subjects also sup-
ports alteration of immune-related processes [40-42].
Using our panel of schizophrenia genes found from
meta-analysis we were able to identify unique features of
the coexpression network and highlight relevant areas of
dysfunction which may contribute to the pathophysi-
ology of schizophrenia. However, our interpretation of
the network model is based on GO enrichment and fur-
ther investigation at the individual gene level will pro-
vide an explanation of higher resolution. We also sought
evidence to support the plausibility of schizophrenia
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From the SZGene (http://www.szgene.org/) database we
compiled the top 45 most reliable genetic associations
based on findings from a meta-analysis [43] . This gene
list was cross-referenced with the top modules from
each network and we found no overlap with the immune
module in either network.
One conclusion of our study is the effects on gene
coexpression patterns in schizophrenia, like those on ex-
pression levels, are subtle in the face of other sources of
variability. This suggests that while seven datasets is a
much larger cohort than used in previous studies,
our study would benefit from having additional data.
Aggregating across a larger number of datasets has been
shown to result in networks more comparable to PPI
networks [44], and is likely to give more reliable interac-
tions, but saturation of some properties was not reported
to be achieved until >20 networks were combined. To help
ameliorate concerns of robustness, we used a jackknife ap-
proach. The results from the jackknife analysis also address
concerns regarding the reuse of datasets for both differen-
tial expression [2] and coexpression. We established that
our findings are not overly sensitive to influence of any
single data set. Also, for our null model comparisons we
applied stringent controls whereby node degree was con-
trolled for. Because node degree is one of the most import-
ant features of a network, it can drive numerous effects on
other topological properties such as clustering coefficient
and shortest path length. Thus controlling for node degree
in generating null distributions is critical for avoiding false
positives. Similarly, because we wished to identify network
features which are associated with schizophrenia, we con-
trolled for “generic” network features by comparing our
schizophrenia gene sets to the properties of other “func-
tionally coherent” gene groups, not just randomly selected
genes. This approach was motivated by recent work from
our group showing that generic multifunctionality effects
can strongly skew the interpretation of gene networks [45].
As is the case with most postmortem brain studies in
schizophrenia, our results should be interpreted in the
context of several caveats. Samples used in this study
were taken from patients having lived with schizophre-
nia for various lengths of time, and often having received
medications. We cannot be sure that the changes we
have identified are direct effects of the illness or are sec-
ondary to an underlying pathology. We were unable to
obtain medication information for all samples used in
this study (specifically, GSE17612 and Mclean66), and
therefore were unable to precisely identify the extent to
which antipsychotic use affects the results of our net-
work analysis. We found that medication-associated
genes overlap to a similar degree with the immune re-
sponse module in both networks, which suggests that
coexpression clustering patterns in schizophrenia arenot driven by medication effects. The effects of other
confounding variables (i.e. age, pH and sex) were also
addressed in a similar manner, however we cannot ex-
clude with certitude the possibility that the network prop-
erties we have identified are still in some way influenced by
these extraneous factors. Also, samples used in our study
comprise a heterogeneous collection of cell types from the
DLPFC. While the majority of our datasets utilized samples
from Brodmann areas 10 and 46, we also included one
dataset from Brodmann area 9. Focusing on samples within
a specific region would be ideal, as we avoid the potential
dilution of cell-specific biological signals associated with
schizophrenia. However, we included samples from all three
Brodmann areas to maximize total sample size in our study
and increase the power of our analysis.
Finally, we wish to stress limitations to the interpret-
ation of coexpression networks. In contrast with other
biological networks (i.e. protein interaction networks or
metabolic networks) whose edges represent well-defined
biological interactions, the edges in a coexpression net-
work are a reduced representation of the correlation
structure of the data. The edges are related to values of
the pairwise correlation coefficient that are calculated
from the expression data of the genes, and are dependent
on the threshold applied to infer those networks. A connec-
tion between two genes in a coexpression network does not
necessarily correspond with a connection in PPI networks,
pathway or regulatory networks [46]. Thus, when studying
gene coexpression networks it is important not to confuse
the edges as direct physical interactions. Indeed, there is
growing evidence that a substantial proportion of the vari-
ance in gene expression among replicate brain samples is
explained by variance in cellular composition [5,6]. Our
work supports this as we identify “modules” that are
strongly associated with different cell type marker genes.
Thus rather than identifying “physical interactions” among
gene products, coexpression patterns to a large degree seem
to reflect cell-type enriched expression, that is, expression
in the same cell, but not necessarily finer levels of granular-
ity such as a pathway. Changes in the composition of such
modules might reflect changes in cellular states in subpop-
ulations of cells, or changes in the associations of cell types
with one another [47]. It is important not to interpret such
differences as meaning that a physical interaction has been
gained or lost among gene products.
Conclusions
In summary we have contributed the largest meta-
analysis of gene coexpression in schizophrenia. We eval-
uated various topological properties of the control and
schizophrenia networks to reveal a shared coexpression
structure between them. Characterization of functional
clusters in each network with cell-type marker genes
displayed differences that link together disease-related
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nia also associate with biologically relevant clusters
providing evidence for systems level dysfunction. Further
research is required to disentangle these network
findings to distinguish primary from secondary disease
phenomena, but we hope our study will encourage new
directions in the network biology of schizophrenia. Finally,
our work demonstrates novel methodological approaches
that can assist in ensuring that coexpression analyses yield
biologically justifiable and robust results.
Methods
Data processing and quality control
Expression profiling data sets were selected on the basis
of microarray platform, use of prefrontal cortex (BA 9,
10 or 46), the availability of information on covariates
such as age, and finally the availability of the raw data
[2]. Details on each of the seven datasets, including the
source citation, can be found in Table 6. Data were
preprocessed as described; briefly, expression levels were
summarized, log2 transformed and normalized for each
individual dataset using the R Bioconductor ‘affy’ pack-
age [48], with default settings for the RMA algorithm.
Sample outliers were removed from each dataset based
on an inter-sample correlation analysis, resulting in a
total of 306 samples (153 from schizophrenia subjects,
153 from unaffected controls) across the seven data sets.
Schizophrenia and control groups had no significant
differences in age and PMI (Table 1). Sex differences
were assessed by use of a chi-squared test for equality of
proportion, and we observed no significant difference
(p = 0.1). Brain pH was significantly different (t-test;
p = 0.001). For each of the seven data sets, batch infor-
mation was obtained using the ‘scan date’ stored in the
CEL files; chips run on different days were considered
different batches and batch effects for each dataset were
removed using the ComBat algorithm [49].
Gene coexpression networks
For each dataset, samples were separated into control
and schizophrenia cohorts. Probes were mapped to
genes using annotations provided in Gemma (http://
www.chibi.ubc.ca/Gemma), which are based on stringent
methods described in [50]. For genes mapping to mul-
tiple probes, the average expression value was retained.
Only genes that were represented in all seven datasets
were considered, leaving a total of 12,582 genes. This
yielded seven expression data matrices for schizophrenia
and seven for controls (one for each study). Separate
networks were constructed for the schizophrenia and
control groups based on previously described methods
[44]. Briefly, a gene expression profile similarity matrix
was computed for each cohort by taking the absolute
value of the Pearson correlation between all possiblegene pairs. Correlation values in the similarity matrix
were replaced by ranks. These similarity matrices were
aggregated by cohort across datasets by taking the mean
rank for each gene pair. We previously showed that this
aggregation procedure is a robust method for producing
high-quality coexpression networks [44]. In keeping
with previous work [44,51], the aggregated matrix was
thresholded at 0.5% sparsity, resulting in an adjacency
matrix of 392,606 connections for each of the control
and schizophrenia cohorts.Random coexpression networks
To evaluate the significance of network measures across
the whole network, formulation of appropriately ran-
domized null models are required. We devised a proced-
ure that results in a random network with the same
number of genes and the same node degree distribution
as the original data. Additionally, the node degree for
each individual gene is preserved (i.e. each gene still has
the same number of connections, but the specific genes
to which it is connected to are scrambled). It has been
previously shown that both PPI and coexpression net-
works show a correlation between node degree and gene
multifunctionality [45]. Thus, by constraining each gene
by its node degree we can systematically assess the sig-
nificance of other topological properties of the network
(i.e. clustering coefficient and shortest path length) while
controlling for any potential multifunctionality bias in
the microarray data. To create random networks, all
gene pairs were assembled into an adjacency list (2 col-
umns, 392,606 rows) and genes on one side of the edge
were permuted. The resulting edges that created self-
connections and/or duplicate gene pairs were isolated
and permutation was re-applied to them. This was done
iteratively until the number of conflicts was reduced to
ten or less. These remaining conflicting edges were re-
moved from the final random network.Network properties
We explored three different network properties, each of
which is briefly described below.Node degree
Each gene can be characterized by the number of con-
nections it has, that is, the number of other genes it is
significantly coexpressed with. This property is called
the node degree. Node degrees were characterized by
their distribution. For many biological networks the de-
gree distribution has been characterized as ‘scale-free’, or
at least ‘heavy tailed’. This can be observed by the qual-
ity of a linear fit of the distribution on log-log scale [52].
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The shortest path length measures the shortest distance
to get from one gene to another gene by traversing edges
in the network. In an un-weighted network this is the
least number of edges traversed to get between the two
genes. We computed shortest paths using Dijkstra’s algo-
rithm [53]. A value is obtained for a gene against every
other gene in the network, and presented as the mean
shortest path length across all genes. Genes without any
direct neighbours are treated as missing values.
Clustering coefficient
The clustering coefficient of a gene indicates how
connected the direct neighbours of a gene are to one an-
other. It is the ratio of the number of connections in the
neighbourhood of a node to the number of connections
if the neighbourhood was fully connected. The clustering
coefficient ranges from zero to one. A value of 1 would in-
dicate that all the neighbours of a node are all connected to
each other, or ‘cliquish’ in nature. A value of 0 would indi-
cate that none of the neighbours of a node are connected
to each other. This measure can only be computed for
nodes that interact with more than one other node.
Schizophrenia meta-signature network analysis
The meta-signature gene set of 25 up- and 73 down-
regulated schizophrenia genes were obtained from the
results of our meta-analysis of differential expression on
the same datasets [2]. Four genes were removed from
the down-regulated gene set as they were not present in
the network, leaving a total of 94 ‘schizophrenia genes’.
Throughout this chapter we will refer to these gene sets
as SZUP and SZDOWN for the genes up- and down-
regulated, respectively. Average values of shortest path
length and clustering coefficient for the SZUP and
SZDOWN gene sets were evaluated within each net-
work. To estimate the relevance of the network mea-
sures for SZUP and SZDOWN, we implemented three
important controls described below.
Random gene set comparison
For each meta-signature gene set, the average values of
shortest path length and clustering coefficient were
compared to a background distribution in each network.
The background distribution was generated by randomly
selecting 1000 gene sets. Random gene sets were con-
strained by size and node degree of the meta-signature gene
set to control for multifunctional bias. To ensure a well-
matched node degree for each random gene set, selection
was done on a per-gene basis by choosing a random gene
within ± 50 of its node degree rank. Z-scores were then
computed to quantify the difference between the mean of
the background distribution to the observed values for each
network measure of SZUP and SZDOWN. For positivez-scores a p-value was computed reflecting how many
random gene sets have values higher than the observed
value. For negative z-scores a p-value was computed
reflecting how many random gene sets have values less
than the observed value.Functional gene set comparison
Although our meta-signature of schizophrenia genes
span a range of cellular functions, they possess a shared
functional feature of altered expression in schizophrenia.
Thus, it is important to assess whether the network
properties we observe with our meta-signature gene sets
are not just a property of gene groups that have lots of
shared functional features. To control for this, we gener-
ated functionally characterized gene sets using the Gene
Ontology (GO). From the GO database (http://www.
geneontology.org/), we obtained 3,230 GO terms for
which the associated gene set size ranged from 10–1000
genes. For each GO term we retrieved all human genes
that were annotated with that term to compile a gene
group for each GO term, also referred to as a functional
gene set. Each of these functional gene sets were evalu-
ated individually by comparison to a background distri-
bution of randomly selected gene sets (of equivalent size
and node degree), within each network. The distribution
of z-scores obtained from 3,230 functional gene groups
was plotted for each network and used to evaluate net-
work properties of the meta-signature gene sets in refer-
ence to other functionally related gene sets.Disease gene set comparison
To assess the network properties of our schizophrenia
meta-signature genes in relation to other sets of disease-
associated genes, we compiled disease gene lists for five
different brain-related disorders. Gene sets were assem-
bled for Alzheimer’s disease (http://www.alzgene.org/),
Parkinson’s disease (http://www.pdgene.org/), multiple
sclerosis (http://www.msgene.org/), and schizophrenia
(http://www.szgene.org/) from their respective gene da-
tabases. Each database has been compiled based on find-
ings from genetic association studies and provide gene
lists on their website. The schizophrenia list obtained
from SZGene (http://www.szgene.org/) comprised only
the top 45 of the most reliable gene associations based
on findings from a SZGene in-house meta-analysis. We
also compiled an Autism spectrum disorder gene list
from Toro et al. [54]. Average values of shortest path
length and clustering coefficient were computed for all
five disease gene sets. Network measures were compared
to a background distribution of randomly selected gene
sets and z-scores were compared against functional gene
set z-score distributions.
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To extract modules (i.e. subset of nodes that are more
densely connected to each other than to nodes outside
the subset) from the control and schizophrenia networks
we implemented a cluster-based algorithm based on
methods described by [5]. Each adjacency matrix was
transformed into a distance matrix by computing the
topological overlap between all probe pairs [55]. Topo-
logical overlap measure (TOM) between two genes is
calculated by comparing the direct connections of each.
If two nodes connect to the same group of other nodes
they are said to have ‘high topological overlap’. We used
a generalization of this measure that enriches TOM’s
sensitivity to longer ranging connections between nodes
by incorporating the number of m-step neighbours
(m = 2) that a pair of node share [55]. The TOM matri-
ces were subjected to WGCNA-based methods [5],
whereby hierarchical clustering was applied with average
linkage, and the resulting tree was used to define net-
work modules.
Enrichment analysis
In order to determine which modules were associated
with schizophrenia we looked for enrichment of differ-
entially expressed genes found from our previous meta-
analysis of the same data [2]. In addition to computing
overlaps of SZUP and SZDOWN with each module, we
also looked at enrichment by utilizing the t-statistic for
the disease effect of each gene. T-statistics were entered
into a Wilcoxon rank-sum test by module and resultant
p-values were corrected for multiple testing using the
Benjamini-Hochberg procedure.
To examine the functional roles encoded by these
modules we used the Gene Ontology (GO) annotations
and evaluated enrichment using the over-representation
analysis (ORA) method in ErmineJ [44,56]. The ORA
method evaluates the genes that meet a selection
criterion to determine if there are gene sets (GO groups)
which are statistically over-represented. The ORA method
requires the entire list of genes and their associated scores
and a score threshold must be selected. Binary scores were
used to evaluate enrichment of each module; a value of 1
was assigned to genes with membership in the module and
a value of 0 assigned to the rest of the genes. P-values
for this method are computed by using the binomial
approximation to the hypergeometric distribution, and
then corrected for multiple testing using the Benjamini-
Hochberg procedure. Modules were also evaluated for CNS
cell type enrichment by cross-referencing the genes in each
module with published lists of neuron, oligodendrocyte and
astrocyte marker genes [15]. Cell type marker lists were
compiled by extracting genes at a lower stringency thresh-
old (as described in [8]) and a high stringency threshold
(greater than 10-fold expression change). Hypergeometricprobabilities were computed to evaluate the significance of
overlap with cell type marker lists in each module.
Additional files
Additional file 1: Table S1. Comparing brain-related disease gene set
properties to functional GO groups.
Additional file 2: Figure S1. Jackknifed network measures. For each
jackknifed network (in which one dataset is removed), we computed
shortest path length and clustering coefficient for SZUP and SZDOWN. To
summarize trends observed in the jackknife analysis, we plotted
clustering coefficient, shortest path length found in the CTL and SZ
networks. Results from SZUP are found in A-B, and SZDOWN in C-D. Each
line represents a different jackknifed network, with the legend indicating
which dataset was removed.
Additional file 3: Table S2. Disease characterization of all coexpression
modules in each network. Modules in each network were characterized
by enrichment of genes that are differentially expressed in schizophrenia.
Disease effect p-values were computed by entering the t-statistic for the
disease effect of each gene into a Wilcoxon rank-sum test by module.
SZUP and SZDOWN are the up- and down-regulated schizophrenia gene
sets previously identified in our meta-analysis [2].
Additional file 4: Table S3. Cell-type marker enrichment of
coexpression modules in each network. For each cluster in the control
and schizophrenia networks we report the number of genes that overlap
with published lists of cell-type marker genes for oligodendrocytes ,
neurons, and astrocyte marker genes provided by [15]. Cell-type
enrichment was computed for a low-stringency list (> 4-fold) and for a
high stringency list (> 10-fold). Hypergeometric probabilities were
computed to evaluate significance of overlap.
Additional file 5: Table S4. Gene Ontology enrichment of top five
disease modules in control.
Additional file 6: Table S5. Gene Ontology enrichment of top five
disease modules in schizophrenia networks, respectively.
Additional file 7: Table S6. Enrichment of genes previously associated
with other covariates.
Additional file 8: Figure S2. Evaluating the effects of covariates on
network modules. For the age up- and pH down regulated genes which
are enriched in the immune response module of CTL, the expression
data was plotted to evaluate differential expression between control and
schizophrenia. A) Genes which remain in the SZ immune module; B)
Genes that are lost from the SZ immune module. In either case, the
expression for these genes is variable within each cohort and differences
in mean expression between cohorts are very small and not significant.
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